With many new lung cancer treatments approved through accelerated tracks based on early-phase (I/II) trial data, we have become increasingly aware of the lack of standards for disclosing toxicities when […] Read more
The relationship between cancer and thromboembolic events as been widely studied since 1895. As we know, venous thromboembolism (VTE) is a well-recognized complication of malignancy, including pulmonary embolism (PE), deep-vein […] Read more
More than 1 million smokers—and counting—have #QuitforCOVID. Read more
The pandemic underscores unmet needs in critical care management and presents an opportunity for learning from patients with cancer. Read more
Lung cancer still holds the top position worldwide in terms of the number of new cases and deaths each year, which in 2018 reached 2.1 million and 1.8 million, respectively.1 Given that roughly 85% […] Read more
Immune checkpoint inhibitors (ICIs) and molecular targeting drugs used against oncogenic drivers, such as EGFR or ALK, have dramatically changed the treatment of NSCLC.1-6 However, treatment options after those drugs […] Read more
In Response To: Palma DA, Olson R, Harrow, S, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. […] Read more
Using LDCT to Boost Lung Cancer Prevention Strategies: A Pro/Con By Ugo Pastorino, MD Now we know from robust randomized trials that systematic screening with low-dose computed tomography (LDCT) of […] Read more
Lung cancer was first identified as a distinct disease in 1761.1 Since this discovery, we have come a long way—both in terms of progress towards understanding the heterogeneous biology of […] Read more